FITX (FITX) Stock Price & Analysis
FITX (FITX) rose 0.00% to USD 0 as of June 10, 2026 at 02:14 UTC, according to Nexqual real-time market data.
FITX last closed at USD 0; the session ranged USD 0–0 on volume of 223,127 shares. Market capitalization is $47,479, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 02:14 UTC.
Key Statistics (as of June 10, 2026 at 02:14 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 223,127 shares |
| Market Cap | $47,479 |
| Exchange | PNK |
Technical Analysis (FITX)
Nexqual's technical model rates FITX "SELL" based on 0 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 02:14 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 0) |
Analyst Ratings (FITX)
Wall Street analysts rate FITX "None", per Nexqual as of June 10, 2026 at 02:14 UTC.
| Consensus Rating | None |
|---|
Earnings (FITX)
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Financials & Fundamentals (FITX)
| Total Revenue | $3.80M |
|---|---|
| Gross Margin | +23.83% |
| Operating Margin | -35.43% |
| Profit Margin | -35.83% |
| ROE | -157.10% |
| Current Ratio | 0.7 |
| Total Cash | $1,510 |
| Total Debt | $26,200 |
| Free Cash Flow | $-206,731 |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Financial Health Score (FITX)
Nexqual rates FITX's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:14 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $2K cash, no debt |
| Cash Flow | Weak — FCF negative: -$207K, burning cash |
| Efficiency | Critical — ROE -157%, ROA -51.4% |
Ownership (FITX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 4.75B |
Source: Nexqual, June 10, 2026 at 02:14 UTC.
Leadership (FITX)
FITX is led by David L. Felten, Chief Medical Director and Director, per Nexqual as of June 10, 2026 at 02:14 UTC.
| Chief Medical Director and Director | David L. Felten |
|---|---|
| Chairman of Medical Advisory Board and Chief Pharmacology & Acquisitions Officer | Sam Alawieh |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EDXC | ENDEXX Corp. | USD 0 | ▲ 0% |
| EAPH | EASTON PHARMACEUTICALS INC | USD 0 | ▲ 0% |
| ERBB | American Green, Inc. | USD 0 | ▲ 0% |
| FSPM | FUSION PHARM INC | USD 0 | ▲ 0% |
| SKTO | SK3 GROUP INC | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:14 UTC. This page is informational and not investment advice.